Cross‐neutralization of RBD mutant strains of SARS‐CoV‐2 by convalescent patient derived antibodies-Reference-Cited by-同舟云学术

Cross‐neutralization of RBD mutant strains of SARS‐CoV‐2 by convalescent patient derived antibodies

Published:2021-08-22 Issue:11 Volume:16 Page:2100207
ISSN:1860-6768
Container-title:Biotechnology Journal
language:en
Short-container-title:Biotechnol. J.

Author:

Lou Yan¹,Zhao Wenxiang²³,Wei Haitao³,Chu Min³,Chao Ruihua²,Yao Hangping¹,Su Junwei¹,Li Yanan³,Li Xiulan³,Cao Yu³,Feng Yanyan³,Wang Ping³,Xia Yongyang³,Shang Yushuan³,Li Fengping³,Ge Pingju⁴,Zhang Xinglin⁴,Gao Wenjing⁴,Song Gaojie²,Du Bing²^ORCID,Liang Tingbo¹,Qiu Yunqing¹,Liu Mingyao²

Affiliation:

1. State Key Laboratory for diagnosis and treatment of infectious diseases Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou China

2. Shanghai Key Laboratory of Regulatory Biology Institute of Biomedical Sciences and School of Life Sciences East China Normal University Shanghai China

3. SymRay Biopharma LLC. Shanghai China

4. Acrobiosystems Inc. Beijing China

Publisher

Wiley

Subject

Molecular Medicine,Applied Microbiology and Biotechnology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/biot.202100207

Reference40 articles.

1. Multi-Epitope Vaccine Design Using an Immunoinformatic Approach for SARS-CoV-2

2. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China

3. A pneumonia outbreak associated with a new coronavirus of probable bat origin